新・血栓止血血管学 抗凝固と線溶

出版社: 金芳堂
著者:
発行日: 2015-10-20
分野: 臨床医学:内科  >  血液
ISBN: 9784765316507
シリーズ: 新・血栓止血血管学
電子書籍版: 2015-10-20 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:8~14営業日

5,720 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,720 円(税込)

目次

  • 表紙
  • 執筆者
  • 推薦の言葉
  • 巻頭言 定着を促進する 記憶の場 としてのテキスト
  • 目次
  • 1部 抗凝固反応
  • 1 血栓と抗凝固系 オーバービュー
  • 1 血栓発症のメカニズムとリスクファクター
  • 2 血栓傾向の検査
  • 3 抗血栓と血栓制御
  • 4 治療戦略としての抗凝固, 抗血栓
  • 2 トロンボモジュリンの基礎と臨床
  • 1 TMの分子構造
  • 2 TMの遺伝子多型と欠損症
  • 3 TMとPC凝固制御系
  • 4 TMと線溶系
  • 5 TMと炎症
  • 6 組換えヒトTM製剤の臨床成績
  • 7 rTMの今後の展開
  • 3 プロテインC, プロテインS, 血管内皮プロテインCレセプターの基礎と臨床
  • 1 プロテインC
  • 2 プロテインS
  • 3 血管内皮プロテインCレセプター ( EPCR )
  • 4 アンチトロンビンの基礎と臨床 ヘパリンコアファクターを含む
  • 1 ATの基礎と臨床
  • 2 HCIIの基礎と臨床
  • 5 組織因子経路阻害因子の基礎と臨床
  • 1 TFPIの構造と存在様式
  • 2 TFPIの機能
  • 3 TFPIの臨床研究
  • 6 プロテインZとプロテインZ依存性プロテアーゼインヒビター
  • 1 PZおよびPZIの構造
  • 2 PZ - PZIの機能
  • 3 PZおよびPZIの生合成と血中濃度
  • 4 PZおよびPZI欠乏症
  • 5 PZ ZPI欠損マウス
  • 6 PZ ZPIと病態との関連
  • 7 今後の展望
  • 2部 線溶反応
  • 7 線溶機構と血栓症 オーバービュー
  • 1 線溶系の基礎
  • 2 線溶系の臨床
  • 8 プラスミノゲン
  • 1 Plg遺伝子変異と表現型
  • 2 Plgの生理機能
  • 3 Plg結合タンパク質
  • 4 Plgの構造
  • 5 Plgの活性化および制御機構
  • 9 プラスミノゲンアクチベーターとその受容体
  • 1 プラスミノゲンアクチベーター ( PA )
  • 2 プラスミノゲンアクチベーター受容体
  • 10 血管内皮細胞と線溶活性調節
  • 1 血管内皮細胞とtPAの分泌
  • 2 血管内皮細胞分泌tPAによるプラスミノゲンアクチベータ活性の発現
  • 11 α2 - プラスミン・インヒビターとヒスチジンリッチ・グリコプロテイン
  • 1 α2 - プラスミン・インヒビター
  • 2 ヒスチジンリッチ・グリコプロテイン
  • 12 PAI - 1
  • 1 PAI - 1の分子機能
  • 2 PAI - 1の生理的機能と病態との関連
  • 3 線溶因子測定とPAI - 1測定の問題点
  • 4 PAI - 1増加と病態 ( 炎症反応と動脈硬化症 ) との関わり
  • 13 TAFIの基礎と臨床
  • 1 カルボキシペプチダーゼとTAFI
  • 2 TAFIaとTAFI zymogenのペプチダーゼ活性
  • 3 TAFIの不安定性と活性制御
  • 4 TAFIによる線溶制御機能
  • 5 血栓性疾患とTAFI
  • 14 TAFIa阻害薬の開発に向けたアプローチ
  • 1 線溶反応とフィブリンC末端Lys残基
  • 2 低分子TAFIa阻害薬
  • 3 抗TAFI TAFIa抗体
  • 15 癌と細胞性線溶
  • 1 血栓上の線溶機能
  • 2 細胞性線溶 癌細胞を中心に
  • 3 細胞性線溶の阻害薬
  • 4 細胞性線溶因子とバイオマーカー
  • 16 Polyhedrocytes その意味論 - 病理と治療へのインパクト
  • 1 Polyhedrocytesとは ? !
  • 2 Polyhedrocytesの意義 止血血栓部位での完全な止血と血管内の血流の保持
  • 3 Polyhedrocytes概念の延長上に
  • 日本語索引
  • 外国語索引
  • 編集者略歴
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1部 抗凝固反応

P.9 掲載の参考文献
P.21 掲載の参考文献
1) Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987 ; 6 : 1891-1897.
2) Zushi M, Gomi K, Yamamoto S, et al. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and antithrombin activity. J Biol Chem 1989 ; 264 : 10351-10353.
5) David-Dufilho M, Millanvoye-Van Brussel E, Topal G, et al. Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. J Biol Chem 2005 ; 280 : 35999-36006.
6) 岡田雅彦, 船越康智, 冨永典男, 他. 胎生期より血栓症を認める先天性トロンボモジュリン異常症の1例. 日本血栓止血学会雑誌 (第30回学術集会抄録集) 2007 ; 18 : 470.
12) Suzuki K, Hayashi T, Nishioka J, et al. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 1989 ; 264 : 4872-4876.
P.28 掲載の参考文献
2) Mosnier LO, Griffin JH. Protein C, Protein S, Thrombomodulin, and the Endothelial Protein C Receptor Pathways. In : Marder VJ, Aird WC, Bennett JS, et al. Hemostasis and thrombosis : basic principles and clinical practice. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins ; 2013 : 300-313.
10) Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency : a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995 ; 73 (5) : 876-889.
11) 津田博子. 先天性プロテインC欠乏症と先天性プロテインS欠乏症. 血液フロンティア 2015 ; 25 (1) : 29-35.
24) Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995 ; 85 (12) : 3524-3531.
25) Comp PC, Thurnau GR, Welsh J, et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986 ; 68 (4) : 881-885.
27) Gandrille S, Borgel D, Ireland H, et al. Protein S deficiency : a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997 ; 77 (6) : 1201-1214.
35) Kurosawa S, Stearns-Kurosawa DJ, Carson CW, et al. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus : lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998 ; 91 (2) : 725-727.
P.36 掲載の参考文献
1) 辻肇. ATの基礎と臨床. In : 一瀬白帝, 編. 図説 血栓・止血・血管学 血栓症制圧のために. 東京 : 中外医学社, 2005 : 483-489.
4) Rosenberg RD. Regulation of the hemostatic mechanisms. In : Stamatoyannopoulos G, ed. The Molecular Basis of Blood Deseases. Philadelphia : Saunders, 1987 : 530-550.
5) Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965 ; 13 : 516. Abstract.
10) Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001 ; 345 : 165-169.
11) 小出武比古. ヘパリンコファクターIIの基礎と臨床. In : 一瀬白帝, 編. 図説 血栓・止血・血管学 血栓症制圧のために. 東京 : 中外医学社, 2005 : 490-497.
12) Van Deerlin VM, Tollefsen DM. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem 1991 ; 266 : 20223-20231.
15) Kondo S, Tokunaga F, Kario K, et al. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). Blood 1996 ; 87 : 1006-1012.
P.42 掲載の参考文献
1) 加藤久雄. TFPIの基礎と臨床. In : 一瀬白帝編. 図説血栓・止血・血管学 : 血栓症制圧のために. 東京 : 中外医学社 2005 : 498-509.
6) Wood JP, Ellery PE, Maroney SA, et al. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2014 ; 34 : 169-176.
8) Hamaru T, Kamikubo Y, Nakahara Y, et al. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett 1998 ; 421 : 197-202.
13) Kobayashi M, Wada H, Wakita Y, et al. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995 ; 73 : 10-14.
17) Broze GJ Jr, Lange GW, Duffin KL, et al. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994 ; 5 : 551-559.
18) Novotny WF, Palmier M, Wun TC, et al : Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991 ; 78 : 394-400.
23) Nordfang O, Valentin S, Beck TC, et al. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991 ; 66 : 464-467.
26) Vincent LM, Tran S, Livaja R, et al : Coagulation factor V (A2440G) causes east Texas bleeding disorder via TFPIα . J Clin Invest 2013 ; 123 : 3777-3787.
P.48 掲載の参考文献
4) Nishijima H, Kawabata S, Kisiel W, et al. Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem 1989 ; 264 : 20320-20325.
6) Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000 ; 96 : 3049-3055.
14) Sugawara H, Iwata H, Souri M, et al. Regulation of human protein Z gene expression by liver-enriched transcription factor HNF-4α and ubiquitous factor Sp1. J Thromb Haemost 2007 ; 5 : 2250-2258.
20) Miletich JP, Broze GJ Jr. Human plasma protein Z antigen : range in normal subjects and effect of warfarin therapy. Blood 1987 ; 69 : 1580-1586.
25) Lichy C, Kropp S, Dong-Si T, et al. A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young. Stroke 2004 ; 35 : 40-45.
38) Kemkes-Matthes B, Nees M, Kuhnel G, et al. Protein Z influences the prothrombotic phenotype in factor V Leiden patients. Thromb Res 2002 ; 106 : 183-185.

2部 線溶反応

P.64 掲載の参考文献
10) Ariens RA. Fibrin (ogen) and thrombotic disease. J Thromb Haemost 2013 ; 11 (Suppl 1) : 294-305.
11) Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-α IIbβ 3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013 ; 122 : 3340-3348.
12) Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992 ; 79 : 1420-1427.
20) 段孝, 宮田敏男. PAI-1阻害薬・そのポテンシャルと臨床への応用. 日本血栓止血学会誌. 2015 ; 26 : 310-317.
23) Noguchi K, Edo N, Ito Y, et al. DS-1040 : a novel selective inhibitor of activated form of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2015 ; 13 (Suppl 2) : 336 (Abstracts PO203-MON).
25) 早川佳奈, 田村志宣, 義間大也, 他. 遺伝子組換えトロンボモジュリン製剤が奏効した維持透析中の解離性大動脈瘤に合併した慢性播種性血管内凝固. 臨床血液 2014 ; 55 : 2300-2305.
29) 一瀬白帝. 後天性凝固異常症のP.O.C. テストによる迅速診断システムの開発に関する研究. 厚生労働科学研究委託費 難治性疾患実用化研究事業 平成26年度委託業務成果報告書. 2015.
34) 阿部康二. 脳梗塞急性期治療のtherapeutic time window. 臨床神経学 2011 ; 51 : 1182-1184.
35) Engesser L, Brommer EJ, Kluft C, et al. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemost 1989 ; 62 : 673-680.
P.73 掲載の参考文献
6) Petersen TE, Martzen MR, Ichinose A, et al. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990 ; 265 : 6104-6111.
13) Drew AF, Kaufman AH, Kombrinck KW, et al. Ligneous conjunctivitis in plsminogen-deficient mice. Blood 1998 ; 91 : 1616-1624.
27) Ichinose A, Fujikawa K and Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Bio Chem 1985 ; 261 : 3486-3489.
32) Law RH, Abu-Ssaydeh D, Whisstock JC. New insights into the structure and function of the plasminogen/plasmin system. Curr Opin Struct Biol 2014 ; 23 : 836-841.
33) 尾崎司, 一瀬白帝. 線溶系の異常. In : 一瀬白帝, 鈴木宏治編. 図説分子病態学. 改訂5版. 東京 : 中外医学社, 2014 : 221-226.
P.80 掲載の参考文献
2) 岡田清孝, 松尾理. 線溶系因子ノックアウトマウスと細胞性線溶. In : 坂田洋一, 小澤敬也編. 別冊・医学のあゆみ血液疾患-State of arts. 東京 : 医歯薬出版, 2005 : 343-348.
3) Ellis V, Dano K. u-Plasminogen activator. In : Barrett AJ, Rawlings ND, Woessner JF, editors. Handbook of Proteolytic Enzymes. San Diego : Academic Press, 1998 : 177-184.
8) King RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells : role of DNA methylation. Int J Cancer 1999 ; 81 : 443-450.
9) Kaht WH, Zheng S, sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001 ; 98 : 257-265.
15) Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982 : 257 : 2912-2919.
17) Kooistra T, Schrauwen Y, Arts J, et al. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994 ; 59 : 233-255.
32) Matsuo O, Okada K, Fukao H, et al. Thromblytic properties of staphylokinase. Blood 1990 ; 76 : 925-929.
41) Ishida C, Ueshima S, Nagai N, et al. Enhancement of fibrinolytic activity in vascular endothelial cells by heterologous expression of adenine nucleotide translocase-1. Blood Coagul Fibrino 2008 ; 21 : 272-278.
P.88 掲載の参考文献
2) Datta YH, Youssoufian H, Marks PW, et al. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells. Blood 1999 ; 94 : 2696-2703.
7) 鈴木優子. 血管内皮細胞におけるtPAの独特な分泌動態とPAI-1による修飾. 血栓止誌 2009 ; 20 : 428-436.
8) Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997 ; 78 : 656-660.
9) Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women : evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998 ; 98 : 2241-2247.
12) 鈴木優子, 佐野秀人, Brzoska Tomasz, 他. リアルタイムイメージングによる修飾tPAの分泌動態. 血栓止血誌, 2014 ; 25 : 259.
19) 鈴木優子, 佐野秀人, Martyna Tomczyk他. 血管内皮細胞発現tPA によるプラスミン産生ならびに線溶能の定量評価と変異型tPAの機能解析. 血栓止血誌 2015 ; 26 : 197.
P.94 掲載の参考文献
4) Holmes WE, Nelles L, Lijnen HR, et al. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987 ; 262 : 1659-1664.
10) Kluft C, Los P, Jie AF, et al. The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. Blood 1986 ; 67 : 616-622.
17) Lijnen HR, Okada K, Matsuo O, et al. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999 ; 93 : 2274-2281.
42) Leebeek FW, Kluft C, Knot EA, et al. Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med 1989 ; 113 : 493-497.
43) Leung LL, Harpel PC, Nachman RL, et al. Histidinerich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983 ; 62 : 1016-1021.
45) Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980 ; 255 : 10214-10222.
46) Silverstein RL, Nachman RL, Leung LL, et al. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem 1985 ; 260 : 10346-10352.
50) Rydengard V, Olsson AK, Morgelin M, et al. Histidinerich glycoprotein exerts antibacterial activity. FEBS J 2007 ; 274 : 377-389.
52) Shigekiyo T, Ohshima T, Oka H, et al. Congenital histidine-rich glycoprotein deficiency. Thromb Haemost 1993 ; 70 : 263-5.
53) Souto JC, Gari M, Falkon L, et al. A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia. Thromb Haemost 1996 ; 75 : 374-5.
56) Angles-Cano E, Gris JC, Loyau S, Schved JF. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism. J Lab Clin Med 1993 ; 121 : 646-653.
60) Lee KN, Tae WC, Jackson KW, et al. Characterization of wild-type and mutant alpha2-antiplasmins : fibrinolysis enhancement by reactive site mutant. Blood 1999 ; 94 : 164-171.
61) Sakata Y, Eguchi Y, Mimuro J, et al. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor. Blood 1989 ; 74 : 2692-2697.
P.104 掲載の参考文献
1) Birktoft JJ, Blow DM. Structure of crystalline -chymotrypsin. V. The atomic structure of tosyl- -chymotrypsin at 2 A resolution. J Mol Biol 1972 ; 68 : 187-240.
4) Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors : structure, function, and regulation. J Biol Chem 1994 ; 269 : 15957-15960.
7) Hakkert BC, Rentenaar JM, van Mourik JA. Monocytes enhance the bidirectional release of type I plasminogen activator inhibitor by endothelial cells. Blood 1990 ; 76 : 2272-2278.
13) Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989 ; 264 : 10867-10871.
15) Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001 ; 13 : 85-94.
16) Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Haematologica 1999 ; 84 : 254-259.
20) Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor 1 : a new prognostic marker in septic shock. Thromb Haemost 1989 ; 61 : 459-462.
30) Eitzman DT, Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000 ; 96 : 4212-4215.
35) 岩城孝行, 長橋ことみ. 先天性線溶因子異常症と妊娠. 産科と婦人科 2013 ; 80 (1) : 47-54.
P.111 掲載の参考文献
1) 関泰一郎, 三浦徳, 細野崇. メタロカルボキシペプチダーゼTAFIの線溶抑制機能と病態生理. 日本血栓止血学会誌 2013 ; 24 (5) : 491-495.
2) 三浦徳, 細野崇, 関泰一郎. TAFIの構造と機能. 日本血栓止血学会誌 2014 ; 24 (5) : 512-515.
5) Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase-B from human plasma. J Biol Chem 1991 ; 266 : 21833-21838.
7) Cote HCF, Stevens WK, Bajzar L, et al. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A and R284A). J Biol Chem 1994 ; 269 : 11374-11380.
15) Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996 ; 88 : 2093-2100.
20) Esmon NL, Owen WG, Esmon CT. Isolation of a membranebound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982 ; 257 : 859-864.
37) van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000 ; 95 : 2855-2859.
38) Libourel EJ, Bank I, Meinardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers ; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein (a) to the absolute risk of venous thromboembolism. Haematologica 2002 ; 87 : 1068-1073.
39) Juhan-Vague I, Morange PE. Very high TAFI antigen levels are associated with a lower risk of hard coronary events : the PRIME Study. J Thromb Haemost 2003 ; 1 : 2243-2244.
40) Juhan-Vague I, Morange PE, Aubert H, et al. HIFMECH Study Group : Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002 ; 22 : 867-873.
46) de Bruijne ELE, Gils A, Rijken DC, et al. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res 2011 ; 127 : 254-258.
56) 奥村暢章, 関泰一郎, 有賀豊彦. TAFIと細胞線溶, 血栓止血誌 2009 ; 20 (4) : 406-411.
P.116 掲載の参考文献
2) Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982 ; 257 (6) : 2912-2919.
6) Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999 ; 94 : 2735-2743.
8) Wang YX, da Cunha V, Vincelette J, et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II : enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007 ; 97 : 54-61.
12) Eriksson H, Jensen E, Sandset PM, et al. CPU inhibition with AZD9684 : profibrinolytic effects in acute PE patients. J Thromb Haemost 2007 ; 5 Supplement 2 : P-S-367.
14) Noguchi K, Edo N, Ito Y, et al. DS-1040 : a novel selective inhibitor of activated form of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2015 ; 13 Supplement S2 : PO203.
15) Noguchi K, Edo N, Ito Y, et al. Effect of DS-1040 on endogenous fibrinolysis and impact on bleeding time in rats. J Thromb Haemost 2015 ; 13 Supplement S2 : AS145.
16) Zhou J, Zamora C, Atiee G, et al. A first-in-human, single ascending dose study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa), in healthy subjects. J Thromb Haemost 2015 ; 13 Supplement S2 : PO621.
P.122 掲載の参考文献
2) Lijinen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochekmistry (Mosc) 2002 ; 67 : 92-98.
3) O'Reilly MS, Wiedershain D, Stetler ?Stenvensen WG, et al. Refulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999 ; 274 : 29568-29571.
6) Samarakoon R, Overstreet JM, Higgins PJ. TGF-β signaling in tissue fibrosis : redox controls, target genes and therapeutic opportunities. Cell Signal 2013 ; 25 (1) : 264-268.
8) Boyd D. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Cancer Res 1989 ; 49 (9) : 2427-2432.
14) Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, et al. The transcription factor nuclear factor-kappa B and cancer. lin Oncol (R Coll Radiol) 2007 ; 19 (2) : 154-161.
17) Samarakoon R, Overstreet JM, Higgins PJ. TGF-β signaling in tissue fibrosis : redox controls, target genes and therapeutic opportunities. Cell Signal. 2013 ; 25 (1) : 264-268.
19) Loridon-Rosa B, Vielh P, Cuadrado C, et al. Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am J Clin Pathol 1988 ; 90 : 7-16.
20) Wu J, Strawn TL, Luo M, et al. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αV β 3 integrin cross talk. Arterioscler Thromb Vasc Biol 2015 ; 35 (1) : 111-120.
24) Burgle M, Koppitz M, Riemer C, et al. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biological chemistry 1997 ; 378 : 231-237.
26) Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002 ; 62 : 2390-2397.
P.128 掲載の参考文献

最近チェックした商品履歴

Loading...